Regulation of the IgE Antibody Response

Progress in Allergy

Vol. 32

Series Editors

Kimishige Ishizaka, Baltimore, Md.; Paul Kallöö, Heisingborg;
Byron H. Waksman, New York, N.Y., and A lain L. de Weck, Bern

S. Karger • Basel • München • Paris • London • New York • Sydney

Regulation of the
IgE Antibody Response

Volume Editor
Kimishige Ishizaka, Baltimore, Md.

Contributors
H. Bazin, Brussels; K. Blaser, Bern; B.E. Bozelka, New Orleans, La.;
K. Ishizaka, Baltimore, Md.; D.H. Katz, La Jolla, Calif.;
T. Kishimoto, Osaka; S.B. Lehrer, New Orleans, La.; P.S. Norman,
Baltimore, Md.; R. Pauwels, Ghent; A.H. Sehon, Winnipeg, Manit.;
A.L. de Weck, Bern

68 figures and 51 tables, 1982

S. Karger • Basel • München • Paris • London • New York • Sydney

Progress in Allergy


Vol. 30: Recent Trends in Allergen and Complement Research. P. Kallöö, Helsingborg (ed.)

Vol. 31: Immunity and Concomitant Immunity in Infectious Diseases. P. Kallöö, Helsingborg
(ed.)
ISBN 3-8055-3464-7

National Library of Medicine, Cataloging in Publication
Regulation of the IgE antibody response
Volume editor, Kimishige Ishizaka; contributors, H. Bazin [et al.], - Basel, New York, Karger 1982
Drug Dosage
The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any change in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.

All rights reserved
No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.

© Copyright 1982 by S. Karger AG, P.O. Box, CH-4009 Basel (Switzerland)
Printed in Switzerland by Buchdruckerei ‘Der Bund’ Bern
ISBN 3-8055-3470-1

Contents

Introduction
K. Ishizaka, Baltimore, Md 1
Mouse IgE
S.B. Lehrer; B.E. Bozelka, New Orleans, La 8
Introduction 9
Why Mouse IgE? 9
Historical Background 10
IgE Biosynthesis 11
Cellular Interactions 11
Site of Synthesis 12
Stimulation of IgE Production 13
Antigen 13
Adjuvants 13
Parasite Infection 14
Non-Specific Methods 14
Suppression of Reaginic Antibody Production 15
Suppressor Cells 15
Tolerance 16
Idiotype Suppression 17
Isotype Suppression 17
Other Mechanisms 20
Ontogeny 20
IgE Isolation 21
IgE from Serum and Ascites Fluid 21
Source of IgE 21
Detection of IgE 23

Contents VI

Purification of IgE 24
IgE Hybridomas 30
IgE Properties 33
Physicochemical Properties 33
Immunoochemical Properties 34
Biological Properties 35
Biological Significance of IgE 36
Allergic Reactions 36
Parasite Infection 37
Neoplasia 37
Future Direction 38
Acknowledgements 39
References 39

IgE and Ig2a Isotypes in the Rat
H. Bazin; R. Pauwels, Brussels/Ghent 52

Historical Background 53
Rat Plasmacytoma Tumours 53
Introduction 53
Origin of the LOU Strain 55
Ileocaecal Malignant Immunocytomas 56
Biosynthesis of Rat Monoclonal Immunoglobulins 59
Interaction of T and B Cells in the IgE Response 266
IgE Class-Specific Helper T Cells and Isotype-Specific Regulation of the
Antibody Response 268
Induction and Characterization of IgE Class-Specific Suppressor T Cells 271
Induction of IgE Class-Specific Suppressor T Cells 271
Are IgE Class-Specific Suppressor T Cells Antigen-Specific or Non-Specific? 274
Suppression of the in vivo IgE Response by Suppressor T Cells 278
T Cell Factors Regulating the IgE Antibody Response 283
IgE Class-Specific Helper or Potentiating Factor(s) 283
IgE Class-Specific Suppressor Factor(s) 286
Target Cells of IgE Class-Specific Suppressor Factor(s) 291
IgE Class-Specific Suppressor T Hybridoma and Its Products 299
IgE-B Cells, the Target Cells of IgE Class-Specific Suppressor Factor 303
Conclusion and Future Prospects 307
Acknowledgment 310
References 310

Immunotherapy
P.S. Norman, Baltimore, Md 318

Introduction 318
‘Prophylactic Inoculations’ 319
Desensitization 320
Blocking Antibodies 320
Controlled Studies 321
Immunologic Correlates 323
IgE Antibodies 326
Specificity of Immunotherapy 327
Antibodies in Secretions 329
Clinically Useful Allergens for Immunotherapy 331
Problem Areas 333
Depot Methods 334
Cross-Linked or Polymerized Antigens 335
Lymphocyte Reactions 336
Suppression of IgE Antibodies 337
References 339